少即是多:何时重复抗菌药物敏感性试验
共纳入18,501次连续药敏试验,发现金黄色葡萄球菌30天内重复培养对任何抗生素耐药风险<10%,肠杆菌目7天内约10%,铜绿假单胞菌风险更高;随访期越长,表型耐药风险越高。若将<10%耐药风险视为可接受,或可省略7天内重复药敏试验。
要点
- 金黄色葡萄球菌30天内重复培养耐药风险<10%。
- 肠杆菌目7天内重复培养耐药风险约10%。
- 铜绿假单胞菌重复培养耐药风险更高。
核心结论
- 若将<10%耐药风险视为可接受,本研究涉及的微生物或可省略7天内重复药敏试验,节省费用、时间并减少实验室浪费。
- 需进一步研究以确定这些节省与使用不适当抗生素治疗患者的微小可能性是否平衡。
研究设计与样本
- 纳入大肠埃希菌、肺炎克雷伯菌、肠杆菌属、铜绿假单胞菌和金黄色葡萄球菌,共18,501次连续药敏试验。
- 药敏试验采用Vitek 2自动化系统,测定基本一致性和分类一致性,并引入基本MIC升高和非耐药到耐药变化的新术语。
主要发现
- 金黄色葡萄球菌重复培养对任何抗生素耐药风险在30天随访内<10%。
- 肠杆菌目重复培养耐药风险在7天随访内约10%。
- 铜绿假单胞菌重复培养耐药风险更高。
- 随访期越长,细菌显示表型耐药的风险越高。
- 某些药物-细菌组合更易发展表型耐药,如大肠埃希菌/阿莫西林-克拉维酸和大肠埃希菌/头孢呋辛。
关键数值与推荐
- 金黄色葡萄球菌30天随访内重复培养对任何抗生素耐药风险<10%。
- 肠杆菌目7天随访内重复培养耐药风险约10%。
- 铜绿假单胞菌重复培养耐药风险高于上述两类。
临床怎么用
- 若接受<10%耐药风险,对金黄色葡萄球菌30天内、肠杆菌目7天内或可省略重复药敏试验。
- 铜绿假单胞菌重复药敏试验风险较高,不宜简单省略。
局限性
- 需进一步研究确定省略重复药敏试验的节省与使用不适当抗生素治疗患者的微小可能性是否平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated the frequency of change of the antimicrobial susceptibility pattern when the same isolate was found in the same patient in various situations. We used laboratory data collected over a period of 8 years (January 2014 to December 2021) at the clinical microbiology laboratory of a tertiary hospital for Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrobial susceptibility tests (AST) were performed using Vitek 2 automated system. We determined essential agreement and categorical agreement, and introduced the new terms essential MIC increase and change from nonresistant to resistant to present changes in antimicrobial susceptibility over time. During the study period, 18,501 successive AST were included. The risk for S. aureus to be resistant to any antibiotic upon repeated culture was <10% during a follow-up of 30 days. For Enterobacterales, this risk was approximately 10% during a follow-up of 7 days. For P. aeruginosa, this risk was higher. The longer the follow-up period, the higher the risk that the bacteria would show phenotypic resistance. We also found that some drug-bug combinations were more likely to develop phenotypical resistance (i.e., E. coli/amoxicillin-clavulanic acid and E. coli/cefuroxime). A potential consequence of our finding is that if we regard a risk of resistance below 10% as acceptable, it may be feasible to omit follow-up AST within 7 days for the microorganisms investigated in this study. This approach saves money, time, and will reduce laboratory waste. Further studies are needed to determine whether these savings are in balance with the small possibility of treating patients with inadequate antibiotics.
引用
- Sarink MJ, Bode LGM, Croughs P, et al. Less Is More: When to Repeat Antimicrobial Susceptibility Testing. J Clin Microbiol. 2023. PMID: 37436180. doi:10.1128/jcm.00463-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。